

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

## Complete if Known



Application Number	09/831,629
Filing Date	August 17, 2001
First Named Inventor	Rina AHARONI
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	AHARONI=5B


RECEIVED

OCT 09 2002

TECH CENTER 1600/2900

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AI	AHARONI et al, "Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease", <u>Immunol Lett</u> 58(2):79-87 (1997)	
	AJ	FRIDKIS-HARELI et al, "Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity", <u>Proc Natl Acad Sci USA</u> 91(11):4872-4876 (1994)	
	AK	FRIDKIS-HARELI et al, "Binding of random copolymers of three amino acids to class II MHC molecules", <u>Int Immunol</u> 11(5):635-641 (1999)	
	AL	LI et al, "Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma", <u>Eur J Pharmacol</u> 342(2-3):303-310 (1998)	
	AM	SCHLEGEL et al, "A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo", <u>Proc Natl Acad Sci USA</u> 93(10):5061-5066 (1996)	
	AN	SELA et al, "Suppressive activity of COP-1 in EAE and its relevance to multiple sclerosis", <u>Bull Inst Pasteur</u> 88:303-314 (1990)	
	AO	TEITELBAUM et al, "Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide", <u>Eur J Immunol</u> 1(4):242-248 (1971)	
	AP	TEITELBAUM et al, "Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1", <u>Proc Natl Acad Sci USA</u> 88(21):9528-9532 (1991)	
	AQ	TEITELBAUM et al, "Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein", <u>Proc Natl Acad Sci USA</u> 89(1):137-141 (1992)	
	AR	TEITELBAUM et al, "Copolymer 1 from the laboratory to FDA", <u>Isr J Med Sci</u> 33(4):280-284 (1997)	

Examiner  
SignatureDate  
Considered

4/7/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

<b>Application Number</b>	09/831,629
<b>Filing Date</b>	August 17, 2001
<b>First Named Inventor</b>	Rina AHARONI
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	AHARONI=5B

~~OCT 09 2002~~

TECH CENTER 1000/2900

OIPE SCTA  
 OCT 08 2002  
 ENT & TRADEMARK OFFICE

[illegible][illegible]

Examiner  
Signature

Date  
Considered

4/7/04

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	09/831,629
<b>Filing Date</b>	August 17, 2001
<b>First Named Inventor</b>	Rina AHARONI
<b>Group Art Unit</b>	<del>1629</del>
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	AHARONI=5B

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

Examiner  
Signature

Date  
Considered

4/7/04

\* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.